NASDAQ / LIVE COMPANY INTELLIGENCE

Protara Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERTARA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / TARA COVERAGE

What’s moving Protara Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

The story matters when it changes Protara Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
02
Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript

Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript

The story matters when it changes Protara Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The story matters when it changes Protara Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The story matters when it changes Protara Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest TARA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-10 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-10 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-26SEC ↗8-KMaterial company eventFiled 2026-06-15 · Period 2026-06-12SEC ↗8-KMaterial company eventFiled 2026-05-13 · Period 2026-05-13SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-12SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-07SEC ↗
EARNINGS / QUARTERLY TRACKER

Protara Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.